Overview A Study of LY3076226 in Participants With Advanced or Metastatic Cancer Status: Completed Trial end date: 2018-03-28 Target enrollment: Participant gender: Summary The main purpose of this study is to evaluate the safety of the study drug known as LY3076226 in participants with advanced or metastatic cancer. Phase: Phase 1 Details Lead Sponsor: Eli Lilly and Company